Literature DB >> 11596156

Lymphatic versus blood vascular endothelial growth factors and receptors in humans.

T A Partanen1, K Paavonen.   

Abstract

Three different growth factor systems have been described acting via endothelial cell-specific receptor tyrosine kinases (RTKs). These are vascular endothelial growth factors (VEGFs), angiopoietins, and ephrins. Recent studies on gene targeting suggest that they play critical roles in embryonic development and contribute to the integrity and responses to environmental factors in the adult vasculature. Coagulation, inflammation, immune response regulation, vascular tone, stromal component synthesis, and angiogenesis are all dependent on the physiological and pathological events that affect endothelial cells in the heart, arteries, veins, and lymphatic vessels. Angiogenesis, the formation of new blood vessels from preexisting ones, takes place in adults only during hormonal control of female reproduction. All other activation of angiogenesis in adulthood occurs in response to injury or pathological processes such as tumorigenesis, diabetes, or inflammatory conditions. Insufficient growth of collateral vessels is a major problem in atherosclerotic cardiovascular disease. Controlled stimulation of angiogenesis would be of therapeutic value. Lymphangiogenesis, the mechanisms involved in the development of lymphatic vessels, was studied intensively nearly a century ago, although since then it has been neglected, perhaps because, unlike the disorders of blood vessels, those of the lymphatic vessels are seldom life-threatening. Interrupting this one-way system can cause severe disorders, including liver dysfunction, genetic disease (e.g., Milroys disease), and degenerative disease (e.g., primary lymphangiosclerosis). Recently, novel growth factors, receptors, cell surface proteins, and transcription factors have been found which play a role in the lymphatic endothelium. These are VEGF-C, VEGF-D, VEGFR-3, LYVE-1, podoplanin, and Prox-1. Until recently lymphatic vessels have been difficult to study due to a lack of appropriate tools. Monoclonal antibodies raised against VEGFR-3 and against its ligands, VEGF-C and VEGF-D, have offered an insight into expression studies in tissues. In this review, we summarize the recent data on VEGFs in the human vasculature. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596156     DOI: 10.1002/jemt.1162

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  9 in total

1.  Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer.

Authors:  Yutaka Yonemura; Yoshio Endo; Kayoko Tabata; Taiichi Kawamura; Hyo-Yung Yun; Etsurou Bandou; Takuma Sasaki; Masahiro Miura
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

2.  Growth hormone promotes lymphangiogenesis.

Authors:  Nadja Erika Banziger-Tobler; Cornelia Halin; Kentaro Kajiya; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

3.  Establishment of lymphangioma model and a study on the promoting effect of murine melanoma cell B16-F1 on the lymphangiogenesis in vitro.

Authors:  Siyuan Chen; Aijun Chen; Changzheng Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

4.  VEGFR-3 neutralization inhibits ovarian lymphangiogenesis, follicle maturation, and murine pregnancy.

Authors:  Joseph M Rutkowski; Jong Eun Ihm; Seung Tae Lee; Witold W Kilarski; Veronique I Greenwood; Miriella C Pasquier; Alexandra Quazzola; Didier Trono; Jeffrey A Hubbell; Melody A Swartz
Journal:  Am J Pathol       Date:  2013-09-13       Impact factor: 4.307

5.  Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents.

Authors:  Jin-Woo Kim; Ekaterina I Galanzha; Evgeny V Shashkov; Hyung-Mo Moon; Vladimir P Zharov
Journal:  Nat Nanotechnol       Date:  2009-08-23       Impact factor: 39.213

6.  Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis.

Authors:  R A A Mohammed; A Green; S El-Shikh; E C Paish; I O Ellis; S G Martin
Journal:  Br J Cancer       Date:  2007-03-13       Impact factor: 7.640

7.  Lymphangiogenic gene therapy with minimal blood vascular side effects.

Authors:  Anne Saaristo; Tanja Veikkola; Tuomas Tammela; Berndt Enholm; Marika J Karkkainen; Katri Pajusola; Hansruedi Bueler; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

8.  Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.

Authors:  Christina Magkou; Lydia Nakopoulou; Christina Zoubouli; Kanelina Karali; Irene Theohari; Panagiotis Bakarakos; Ioanna Giannopoulou
Journal:  Breast Cancer Res       Date:  2008-06-03       Impact factor: 6.466

Review 9.  Review on the Lymphatic Vessels in the Dental Pulp.

Authors:  Kamila Wiśniewska; Zbigniew Rybak; Maria Szymonowicz; Piotr Kuropka; Maciej Dobrzyński
Journal:  Biology (Basel)       Date:  2021-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.